Russian strategy in Ukraine under pressure. Longer term impact of military action on economy

Emerging markets will dominate global growth - where 85% of humanity lives. Economy keynote speaker

Trust is the most important thing. Future of logistics and supply chain management - keynote speaker

Future of Sales and Marketing beyond COVID - hybrid event in Vilnius: physical audience of 800 + 300 virtual. Digital marketing, location marketing. How to create MAGIC in new marketing campaigns. Future of Marketing Keynote Speaker

Chances of 2 people in 70 having same birthday? Managing Risk in Banking and Financial Services. Why the greatest risks are combinations of very unlikely events, which happen far more often than you expect. Keynote speaker on risk management

Compliance is Dead. How to build trust. Reputation of banks and financial services. Compliance Risks. Why 100% compliance with regulations, ESG requirements etc is often not enough to prevent reputational damage

Life's too short to do things you don't believe in! Why passionate belief in the true value of what you are selling or doing is the number one key to success. Secret of all leadership and marketing - keynote for 1100 people in Vilnius October 2021

Why you can't innovate on Zoom or Teams meetings - Innovation is almost impossible unless breathing same air, in same room

Why the key to rapid innovation is team diversity - survey global CEOs. Innovation keynote speaker

Future Manufacturing 5.0. Lessons from personal life for all manufacturers. Manufacturing Keynote

Future of Manufacturing: diagnostics; predictive analytics, little data and cybersecurity. Keynote

Manufacturing 5 0: The truth about robots, robotics and automation. Future of Manufacturing Keynote

New hope for multiple sclerosis - Interferon B

Futurist Keynote Speaker: Posts, Slides, Videos - Future Health Care and Pharma Keynote Speaker

Interferon b treatment helps multiple sclerosis recovery and survival.  That's according to the Interferon b PRISMS study by Dr George Ebers, Division of Neurology, London Health Sciences Centre Ontario in the Lancet (7 November 1998). 

(Note: Natalizumab also seems to slow down MS. David Miller at the Institute of Neurology in London has found that monthly injections reduce the number of new MS lesions by 90% compared to those given a placebo treatment. Natalizumab seems to work by preventing immune cells from crossing the blood brain barrier, which is further evidence that white cells are involved in attacking the fatty insulator myelin sheath surrounding normal brain fibres. (New England Journal of Medicine vol 348, p15))

Prof Ludwig Kappos also found the same Interferon b treatment effect in the European Study Group. Both found interferon b-1a reduces clinical relapses in multiple sclerosis, delays the time before there is serious disability and reduces the number of new episodes.

Multiple sclerosis (MS) affects 1.1 million world-wide.  It is a progressive, disabling disease of the central nervous system which is incurable.  The first interferon study involved 560 people with relapsing-remitting multiple sclerosis, the second consisted of 718 with secondary-progressive MS followed for three years, randomly allocated to placebo and interferon b.  Calls are now being made for governments to make interferon b available immediately for all with multiple sclerosis but it is very expensive.

What is the truth about MS progression?

The answer is that every person is different.  However large studies reveal common patterns.  MS results from damage to the sheath around nerve fibres (demyelination) in the central nervous system.  Typicla features are loss of vision (may be partial, patchy and with good recovery), weakness, numbness and changes in mood or personality.   The classic features of multiple sclerosis are a sudden event which is obvious, with almost total or apparently complete recovery.  We don't know what causes MS.

Relapsing-remitting MS -  85% of patients have one or more episodes followed by complete or partial recovery.  Patients are stable between relapses.

Progressive MS - in 15% of multiple sclerosis cases the condition continues to worsen progressively.

Secondary-progressive MS - within ten years, half of those with relapsing-remitting MS experience gradually worsenning disability, with or without obvious episodes of further nerve damage.

e-mails:  [email protected] and [email protected]

Related news items:
Newer news items:
Older news items:

Thanks for promoting with Facebook LIKE or Tweet. Really interested to read your views. Post below.

Join the Debate! What are your own views?



Search for your future

Our cookie policy

We use cookies for statistical purposes. To comply with the e-Privacy Directive we need to ask your consent to place these cookies on your computer.

Your use of this site indicates acceptance of these terms. I accept